Taipei, Taiwan-headquartered Lumosa Therapeutics Co., Ltd. has announced that its lead drug candidate for acute ischemic stroke, LT3001, has received approval from the US FDA to begin Phase I clinical trials.Read more
Taipei, Taiwan-headquartered OBI Pharma, Inc., (TPex: 4174), announced last week that an agreement with Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) had been made to acquire TH-3424, a first-in-class novel small-molecule prodrug that selectively targets cancers overexpressing the enzyme aldo-keto reductase 1c3 (AKR1C3).Read more
In an interview with finance website Deal Street Asia, Singapore-headquartered drug development firm Asian Pharmaceuticals’ CEO Dr Carl Firth discussed why he took the company public in Taiwan and not Singapore, Europe or the US.Read more
US-based GE Healthcare announced this week that Taiwan’s United BioPharma Inc. (UBP) had selected GE Healthcare’s FlexFactory manufacturing platform for its new facility in Hsinchu, Taiwan, focusing on late-stage clinical and commercial production capacity of therapeutic monoclonal antibodies.Read more
Taiwan’s biotech and pharmaceutical industry was one of the first to be named in the original Tsai Administration’s 5+2 economic policy to transform the nation’s economic structure, and is viewed as the upcoming medical treatment trend that Taiwan cannot miss out on, said Johnsee Lee, the Honorary Chairman of Taiwan Bio Industry Organization (Taiwan BIO) during the Precision Medicine Industry Forum 2017 in Taipei, Wednesday.Read more
Chipscreen Biosciences Ltd. executives She Liang-ji, VP, Oncology Division, and Xin Fu, Medical Affairs Manager (left) meeting with GNTbm's President Alex Chen (right) in Taipei, Taiwan, in February this year.
GNT Biotech & Medicals Co., Ltd., (GNTbm) (TPEx: 7427) has announced that the anticancer drug Chidamide (HBI-8000), an epigenetic regulator developed by Chipscreen Biosciences Ltd., of Shenzhen, China, had received approval from the Taiwan Food and Drug Administration (TFDA) to begin a Phase III clinical trial in Taiwan for hormone receptor-positive, HER-2 negative late stage breast cancer.Read more